For the World Kidney Day Joint Steering Committee. Внимание на пробелы в лечении заболеваний почек: воплощаем то, что мы знаем, в то, что мы делаем


DOI: https://dx.doi.org/10.18565/nephrology.2024.2.93-110

Valerie A. Luyckx, Katherine R. Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W.S. Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A. Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci

1) Кафедра общественного и глобального здравоохранения, Институт эпидемиологии, биостатистики и профилактики, Цюрихский университет, Цюрих, Швейцария; 2) Отделение патологии почек, медицинский факультет, Женская больница Бригама, Гарвардская медицинская школа, Бостон, Массачусетс, США; 3) Кафедра педиатрии и здоровья детей, Кейптаунский университет, Кейптаун, Южная Африка; 4) Медицинский исследовательский центр Провиденса, Providence Inland Northwest Health, Спокан, Вашингтон, США; 5) Отделение нефрологии, медицинский факультет Вашингтонского университета, Сиэтл, Вашингтон, США; 6) Отделение нефрологии, Больница Каирского университета, Каир, Египет; 7) Отделение нефрологии и минерального обмена, Национальный институт медицинских наук и питания Сальвадора Зубирана, Мехико, Мексика; 8) Отделение медицины и терапии, Больница принца Уэльского, Китайский университет Гонконга, Шатин, Гонконг, Китай; 9) Отделение нефрологии, больница Петерфи, Будапешт, Венгрия; 10) Консультативная группа по связям с пациентами Международного общества нефрологов; 11) Фонд исследования почек Тамилнада (ТАНКЕР), Ченнаи, Индия; 12) 2-е отделение нефрологии, Медицинская школа университетской больницы AHEPA, Университет Аристотеля в Салониках, Салоники, Греция; 13) Медицинский факультет, Медицинский колледж, Нигерийский университет, Итуку-Озалла, Энугу, Нигерия; 14) Отдел системы здравоохранения, политики и управления, Школа общественного здравоохранения и первичной медико-санитарной помощи Жокей-клуба, Китайский университет Гонконга, Гонконг; 15) 2-е отделение нефрологии, Медицинская школа университетской больницы AHEPA, Университет Аристотеля в Салониках, Салоники, Греция; 16) Итальянский фонд почек, Рим, Италия; 17) Объединенный руководящий комитет Всемирного дня почек указан в Приложении; 18) VAL и KRT являются совместными первыми авторами; 19) MK, FL, VR, MS и BW являются представителями пациентов Консультативной группы по связям с пациентами Международного общества нефрологов
Исторически сложилось так, что с момента появления клинических доказательств эффективности новых методов лечения до внедрения их в повседневную практику требуется в среднем 17 лет. С учетом доступности в настоящее время высокоэффективных методов лечения для профилактики или отсрочки начала и прогрессирования заболеваний почек это слишком долгий период. Настало время сократить разрыв между тем, что мы знаем, и тем, что мы делаем. Существуют четкие рекомендации по профилактике и лечению распространенных факторов риска заболеваний почек, таких как артериальная гипертензия и сахарный диабет, но лишь у небольшого числа людей во всем мире диагностируют эти заболевания и еще меньше людей получают целевое лечение. Кроме того, подавляющее большинство людей, живущих с заболеваниями почек, не подозревают о своем состоянии, поскольку на ранних стадиях они часто бывают бессимптомными. Даже при установленном диагнозе многие пациенты не получают надлежащего лечения заболевания почек. С учетом серьезных последствий прогрессирования заболевания почек, почечной недостаточности или смерти крайне важно своевременно назначать правильное лечение. Возможности ранней диагностики и лечения заболеваний почек должны быть максимально расширены, начиная с уровня первичного звена здравоохранения. Существует множество системных препятствий: от пациента до врача, от систем здравоохранения до социальных факторов. Чтобы сохранить и улучшить здоровье почек для всех людей во всем мире, необходимо иметь понимание о каждом из этих препятствий, чтобы без дальнейших задержек разрабатывать и внедрять рациональные решения.

Литература



  1. Jager K.J., Kovesdy C., Langham R. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96 (2019) 1048–50.

  2. Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Accessed November 18, 2023. http://vizhub.healthdata.org/gbd-compare

  3. Luyckx V.A., TonelliM., Stanifer J.W., The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 96 (2018) 414–22D.

  4. International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed. Accessed November 18, 2023. https://www.theisn.org/initiatives/global-kidney-health-atlas/

  5. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 (2020) 709–33.

  6. Vanholder R., Annemans L., Brown E. et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 13 (2017) 393–409.

  7. Nguyen-Thi H.Y., Le-Phuoc T.N., Tri Phat N. et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights 14, 2021.

  8. US Renal Data System. Healthcare expenditures for persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd

  9. Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease. Accessed January 16, 2024. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-of-early-detection-and-treatment.pdf.

  10. Ke С., Liang J., Liu М. et al. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990–2019: results from the global burden of disease study 2019. BMC Nephrol 23 (2022) 17.

  11. Gregg E.W., Buckley J., Ali M.K. et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet 401 (2023) 1302–12.

  12. Geldsetzer Р., Manne-Goehler J., Marcus M.E. et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 394 (2019) 652–62.

  13. Chu L., Bhogal S.K., Lin P. et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes 46 (2022) 464–72.

  14. Levin А., Tonelli М.,Bonventre J. et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390 (2017) 1888–917.

  15. Stengel B., Muenz D., Tu C. et al. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep 6 (2021) 437–48.

  16. Chu C.D., Chen M.H., McCulloch C.E. et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med 3 (2021) 576–85.e1.

  17. Ene-Iordache B., Perico N., Bikbov B. et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Global Health 4 (2016) e307–19.

  18. Gummidi B., John O., Ghosh A. et al. A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney Int Rep 5 (2020) 2246–55.

  19. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102 (5S) (2022) S1–S127.

  20. Nicholas S.B., Daratha K.B., R.Z. Alicic K.B. et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes Metab 25 (2023) 2970–79.

  21. Grams M.E., Yang W., Rebholz C.M. et al. Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 70 (2017) 337–46.

  22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. https://doi.org/10.1016/j.kint.2023.10.018

  23. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99 (3S) (2021) S1–S87.

  24. Tuttle K.R., Alicic R.Z., Duru O.K. et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open 2, 2019.

  25. Ismail W.W., Witry M.J., Urmie J.M. The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm 29 (2023) 449–463.

  26. Heerspink H.J.L., Vart P., Jongs N. et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab 25 (2023) 3327–36.

  27. Nuffield Department of Population Health Renal Studies Group. SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400 (2022) 1788–801.

  28. Fernández-Fernandez В., Sarafidis Р., Soler M.J. et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 16 (2023) 1187–98.

  29. McEwan P., Boyce R., Sanchez J.J.G. et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant 38 (2023) 1260–1270.

  30. Vanholder R., Annemans L., Braks М. et al. Inequities in kidney health and kidney care. Nat Rev Nephrol 19 (2023) 694–708.

  31. Agarwal R., Filippatos G., Pitt B. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43 (2022) 474–84.

  32. Tuttle K.R., Bosch-Traberg H., Cherney D.Z.I. et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int 103 (2023) 772–81.

  33. Rubin R. It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA 329 (2023) 1333–36.

  34. World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCD-GAP). Accessed November 18, 2023. https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gap-final-report.pdf?sfvrsn=55b22b89_5&download=true

  35. Kruk M.E., Gage A.D., Joseph N.T. et al. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 392 (2018) 2203–12.

  36. Kingori Р., Peeters Grietens К. Abimbola S. et al. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health 6, 2023.

  37. Pan American Health Organization Quality control of medicines. Accessed November 18, 2023. https://www.paho.org/en/topics/quality-control-medicines.

  38. K.R. Tuttle, L. Wong, W. St Peter et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 17 (2022) 1092–1103.

  39. R. Kalyesubula, A.L. Conroy, V. Calice-Silva et al. Screening for kidney disease in low- and middle-income countries. Semin Nephrol 42, 2022.

  40. A. Francis, M.I. Abdul Hafidz, U.E. Ekrikpo et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int 102 (2022) 969–973.

  41. J. Rangaswami, K. Tuttle, M. Vaduganathan, Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes 13, 2020.

  42. J.J. Neumiller, R.Z. Alicic, K.R. Tuttle, Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis 28 (2021) 318–327.

  43. S.R. Mishra, D. Neupane, D. Preen et al. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health 11 (2015) 43.

  44. R. Joshi, O. John, V. Jha, The potential impact of public health interventions in preventing kidney disease. Semin Nephrol 37 (2017) 234–244.

  45. A. Patel, D. Praveen, A. Maharani et al. Association of multifaceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiol 4 (2019) 978–986.

  46. A. Ardavani, F. Curtis, K. Khunti et al. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep 6, 2023.

  47. C.F. Sherrod, S.L. Farr, A.J. Sauer, Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?, Eur Heart J 44 (2023) 1970–1972.

  48. C. Ramakrishnan, N.C. Tan, S. Yoon et al. Healthcare professionals' perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Res 22 (2022) 560.

  49. J. Porter, C. Boyd, M.R. Skandari et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med 38 (2023) 147–155.

  50. C.A. Peralta, J. Livaudais-Toman, M. Stebbins et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis 76 (2020) 636–644.

  51. P. Rios, L. Sola, A. Ferreiro et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One 17, 2022.

  52. J.K. Stevenson, Z.C. Campbell, A.C. Webster et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev 8 (2019) Cd012379.

  53. Tuot D.S., Crowley S.T., Katz L.A. et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res 6, 2022.

  54. Verberne W.R., Stiggelbout A.M., Bos W.J.W. et al. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics 23 (2022) 47.

  55. A. Taha, Y. Iman, J. Hingwala et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med 4, 2022.

  56. Essue B.M., Laba M., Knaul F. et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. in: D.T. Jamison, H. Gelband, S. Hortonet al. (Eds.), Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017. https://doi.org/10.1596/978-1-4648-0527-1_ch6

  57. Khatib R., McKee M., Shannon H. et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016) 61–9.

  58. Kamath N., Iyengar A.A, Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr 84 (2017) 822–85.

  59. Cirillo L., Ravaglia F., Errichiello C. et al. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol 37 (2022) 2997–3008.

  60. Donohue J.F., Elborn J.S., Lansberg P. et al. Bridging the "know-do" gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh 15 (2023) 103–19.

  61. Population Health Research Institute. Polypills added to WHO essential medicines list. Accessed November 18, 2023. https://www.phri.ca/eml/.

  62. Sepanlou S.G., Mann J.F.E., Joseph P. et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol 18 (2023) 1408–15.

  63. Dev V., Mittal A., Joshi V. et al. Cost analysis of telemedicine use in paediatric nephrology-the LMIC perspective. Pediatr Nephrol 39 (2024) 193–201.

  64. Musacchio N., Zilich R., Ponzani P. et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes 15 (2023) 224–36.

  65. Zuniga C., Riquelme C., Muller H. et al. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep 5 (2020) 920–23.

  66. van der Horst D.E.M., HofstraN., van Uden-Kraan C.F. et al. Shared decision making in health care visits for CKD: patients' decisional role preferences and experiences. Am J Kidney Dis 82 (2023) 677–86.

  67. Hole B., Scanlon M., Tomson C. Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J 16 (2023) i12–i19.


Об авторах / Для корреспонденции


Dr. Stefanos Roumeliotis, доктор медицинских наук, нефролог, 2-е отделение нефрологии, Больница AHEPA, Медицинская школа, Университет Аристотеля в Салониках, ул. Св. Кириакиди, 1, 54636, Салоники, Греция. Тел.+302310994694. электронная почта: st_roomliotis@hotmail.com
* Valerie A. Luyckx, Департамент общественного и глобального здравоохранения, Институт эпидемиологии, биостатистики и профилактики, Цюрихский университет, Хиршенграбен 84, Цюрих 8001, Швейцария. Электронная почта: valerie.luyckx@uzh.ch
* Katherine R. Tuttle, Медицинский исследовательский центр Провиденса, Провиденс Внутреннее Северо-Западное здравоохранение, 105 W 8th Avenue, Suite 250 E, Спокан, Вашингтон 99204, США. Электронная почта: katherine.tuttle@providence.org


Похожие статьи


Бионика Медиа